u/Aggravating-Sky7564

**These bills don't have a scheduled hearing, but it's better to get ahead of it. I believe NY's session ends June 4th, and if they believe it's a major issue, it can move quickly.

NY A10969/S10514

“Synthetic Kratom Kills Act”

which would ban synthetic or adulterated kratom products, flavored products aimed at minors, vape/injectable kratom products, and products with over 2% 7-hydroxymitragynine. It also bans sales to anyone under 21 and requires child-resistant packaging, testing, and clear labeling.

We want fair regulation, prohibition!

Sponsors:

S10514: Senator Jessica Scarcella-Spanton (D) spanton@nysenate.gov

A10969: Asm. Jacob Blumencranz ( R)

blumencranzj@nyassembly.gov

Both referred to Health Committee:

Gustavo Rivera (D, Chair) grivera@nysenate.gov

Jacob Ashby ( R) ashby@nysenate.gov

Samra G. Brouk (D) brouk@nysenate.gov

Patrick M. Gallivan (R ) gallivan@nysenate.gov

Kristen Gonzalez (D) gonzalez@nysenate.gov

Robert Jackson (D) jackson@nysenate.gov

Jackson M. Martins (R ) martins@nysenate.gov

Rachel May (D) may@nysenate.gov

Zellnor Myrie (D) myrie@nysenate.gov

Kevin S. Parker (D) parker@nysenate.gov

Steven D. Rhoads (R ) rhoads@nysenate.gov

Christopher Ryan (D) chrisryan@nysenate.gov

Daniel G. Stec (R ) stec@nysenate.gov

Sam Sutton (D) sutton@nysenate.gov

Lea Webb (D) leawebb@nysenate.gov

Below is somewhat of a template and points to touch on when emailing NY senators. Also, always add your story in an email and explain how a ban would affect you.

“I am writing to as a consumer to respectfully oppose bills A10969 and S10514. While parts of these bills involve reasonable consumer protections, they would also ban kratom products containing over 2% 7-hydroxymitragynine (7-OH), which could severely impact responsible consumers who rely on these products.

I ask that you carefully consider the science. 7-hydroxymitragynine (7-OH) is a naturally occurring alkaloid found in the kratom plant (Mitragyna speciosa),

a tropical tree native to Southeast Asia. It is not a novel synthetic drug, nor is it a laboratory invention. 7-OH is naturally produced by the body after consuming kratom’s primary alkaloid, mitragynine. Banning 7OH could therefore have broader implications for kratom access as a whole, beyond what may be intended.

Policies should be grounded in science, evidence, and consumer safety—not confusion or overly broad classification. Many responsible consumers rely on 7OH as part of their daily lives, and sweeping restrictions could have serious unintended consequences. Individuals who depend on it for health or harm reduction may suffer greatly. Removing access risks pushing people toward unsafe alternatives, including illicit substances, or leaving them unable to function in daily life.

Rather than prohibition, I strongly encourage you to consider responsible regulation and consumer protections.

I respectfully ask that you oppose these bills or amend them to ensure fair, evidence-based treatment of natural kratom alkaloids and harm-reduction options.”

Calling All Advocates the fiscal year is almost over but we still need to stay VIGILANT!!!

🚨 NEW YORK 7-OH BILL ALERT — ACTION NEEDED 🚨

New York Senate Bill S8925A is now scheduled for consideration in the Senate Consumer Protection Committee on:

📅 May 20, 2026

🕥 10:30 AM

📍 Room 804 LOB

This bill would severely restrict or effectively eliminate most 7-hydroxymitragynine products currently on the market by imposing extremely low allowable limits.

This is NOT the time to stay silent.

If 7-OH has helped your quality of life, helped you stay away from illicit opioids, helped with pain, work, motivation, or daily functioning — NOW is the time to respectfully speak up.

📞 CONTACT THE SENATE CONSUMER PROTECTION COMMITTEE MEMBERS:

• Jeremy Cooney (Committee Chair)

Albany Office: (518) 455-2485

• Leroy Comrie

(518) 455-3531

• Pamela Helming

(518) 455-2366

• Rachel May

(518) 455-2111

• Roxanne Persaud

(518) 455-2788

• Patricia Fahy

(518) 455-2225

Emails for Senate Consumer Protection Committee

Jeremy Cooney (Chair)

cooney@nysenate.gov

Leroy Comrie

comrie@nysenate.gov

Pamela Helming

helming@nysenate.gov

Rachel May

may@nysenate.gov

Roxanne Persaud

Persaud@nysenate.gov

Patricia Fahy

Fahy@nysenate.gov

📢 MESSAGE TO LAWMAKERS:

Please regulate responsibly — don’t push consumers toward dangerous illicit opioids by banning products adults rely on.

Support:

✔ Age restrictions

✔ Testing requirements

✔ Labeling standards

✔ Responsible retail controls

But oppose prohibition that removes access entirely.

Keep calls respectful, calm, and professional. Angry calls hurt the cause.

Even a 2-minute phone call matters.

Example:

“Hi, my name is ___ and I’m asking the Senator to oppose S8925A as written. I support reasonable regulation and safety standards, but not prohibition of products many adults rely on. Please consider consumer harm reduction and personal freedom before supporting this bill.”

Share this everywhere. The hearing is May 20.

Calling All Advocates the fiscal year is almost over but we still need to stay VIGILANT!!!

🚨 NEW YORK 7-OH BILL ALERT — ACTION NEEDED 🚨

New York Senate Bill S8925A is now scheduled for consideration in the Senate Consumer Protection Committee on:

📅 May 20, 2026

🕥 10:30 AM

📍 Room 804 LOB

This bill would severely restrict or effectively eliminate most 7-hydroxymitragynine products currently on the market by imposing extremely low allowable limits.

This is NOT the time to stay silent.

If 7-OH has helped your quality of life, helped you stay away from illicit opioids, helped with pain, work, motivation, or daily functioning — NOW is the time to respectfully speak up.

📞 CONTACT THE SENATE CONSUMER PROTECTION COMMITTEE MEMBERS:

• Jeremy Cooney (Committee Chair)

Albany Office: (518) 455-2485

• Leroy Comrie

(518) 455-3531

• Pamela Helming

(518) 455-2366

• Rachel May

(518) 455-2111

• Roxanne Persaud

(518) 455-2788

• Patricia Fahy

(518) 455-2225

Emails for Senate Consumer Protection Committee

Jeremy Cooney (Chair)

cooney@nysenate.gov

Leroy Comrie

comrie@nysenate.gov

Pamela Helming

helming@nysenate.gov

Rachel May

may@nysenate.gov

Roxanne Persaud

Persaud@nysenate.gov

Patricia Fahy

Fahy@nysenate.gov

📢 MESSAGE TO LAWMAKERS:

Please regulate responsibly — don’t push consumers toward dangerous illicit opioids by banning products adults rely on.

Support:

✔ Age restrictions

✔ Testing requirements

✔ Labeling standards

✔ Responsible retail controls

But oppose prohibition that removes access entirely.

Keep calls respectful, calm, and professional. Angry calls hurt the cause.

Even a 2-minute phone call matters.

Example:

“Hi, my name is ___ and I’m asking the Senator to oppose S8925A as written. I support reasonable regulation and safety standards, but not prohibition of products many adults rely on. Please consider consumer harm reduction and personal freedom before supporting this bill.”

Share this everywhere. The hearing is May 20.

Calling All Advocates the fiscal year is almost over but we still need to stay VIGILANT!!!

🚨 NEW YORK 7-OH BILL ALERT — ACTION NEEDED 🚨

New York Senate Bill S8925A is now scheduled for consideration in the Senate Consumer Protection Committee on:

📅 May 20, 2026

🕥 10:30 AM

📍 Room 804 LOB

This bill would severely restrict or effectively eliminate most 7-hydroxymitragynine products currently on the market by imposing extremely low allowable limits.

This is NOT the time to stay silent.

If 7-OH has helped your quality of life, helped you stay away from illicit opioids, helped with pain, work, motivation, or daily functioning — NOW is the time to respectfully speak up.

📞 CONTACT THE SENATE CONSUMER PROTECTION COMMITTEE MEMBERS:

• Jeremy Cooney (Committee Chair)

Albany Office: (518) 455-2485

• Leroy Comrie

(518) 455-3531

• Pamela Helming

(518) 455-2366

• Rachel May

(518) 455-2111

• Roxanne Persaud

(518) 455-2788

• Patricia Fahy

(518) 455-2225

Emails for Senate Consumer Protection Committee

Jeremy Cooney (Chair)

cooney@nysenate.gov

Leroy Comrie

comrie@nysenate.gov

Pamela Helming

helming@nysenate.gov

Rachel May

may@nysenate.gov

Roxanne Persaud

Persaud@nysenate.gov

Patricia Fahy

Fahy@nysenate.gov

📢 MESSAGE TO LAWMAKERS:

Please regulate responsibly — don’t push consumers toward dangerous illicit opioids by banning products adults rely on.

Support:

✔ Age restrictions

✔ Testing requirements

✔ Labeling standards

✔ Responsible retail controls

But oppose prohibition that removes access entirely.

Keep calls respectful, calm, and professional. Angry calls hurt the cause.

Even a 2-minute phone call matters.

Example:

“Hi, my name is ___ and I’m asking the Senator to oppose S8925A as written. I support reasonable regulation and safety standards, but not prohibition of products many adults rely on. Please consider consumer harm reduction and personal freedom before supporting this bill.”

Share this everywhere. The hearing is May 20.

Calling All Advocates the fiscal year is almost over but we still need to stay VIGILANT!!!

🚨 NEW YORK 7-OH BILL ALERT — ACTION NEEDED 🚨

New York Senate Bill S8925A is now scheduled for consideration in the Senate Consumer Protection Committee on:

📅 May 20, 2026

🕥 10:30 AM

📍 Room 804 LOB

This bill would severely restrict or effectively eliminate most 7-hydroxymitragynine products currently on the market by imposing extremely low allowable limits.

This is NOT the time to stay silent.

If 7-OH has helped your quality of life, helped you stay away from illicit opioids, helped with pain, work, motivation, or daily functioning — NOW is the time to respectfully speak up.

📞 CONTACT THE SENATE CONSUMER PROTECTION COMMITTEE MEMBERS:

• Jeremy Cooney (Committee Chair)

Albany Office: (518) 455-2485

• Leroy Comrie

(518) 455-3531

• Pamela Helming

(518) 455-2366

• Rachel May

(518) 455-2111

• Roxanne Persaud

(518) 455-2788

• Patricia Fahy

(518) 455-2225

Emails for Senate Consumer Protection Committee

Jeremy Cooney (Chair)

cooney@nysenate.gov

Leroy Comrie

comrie@nysenate.gov

Pamela Helming

helming@nysenate.gov

Rachel May

may@nysenate.gov

Roxanne Persaud

Persaud@nysenate.gov

Patricia Fahy

Fahy@nysenate.gov

📢 MESSAGE TO LAWMAKERS:

Please regulate responsibly — don’t push consumers toward dangerous illicit opioids by banning products adults rely on.

Support:

✔ Age restrictions

✔ Testing requirements

✔ Labeling standards

✔ Responsible retail controls

But oppose prohibition that removes access entirely.

Keep calls respectful, calm, and professional. Angry calls hurt the cause.

Even a 2-minute phone call matters.

Example:

“Hi, my name is ___ and I’m asking the Senator to oppose S8925A as written. I support reasonable regulation and safety standards, but not prohibition of products many adults rely on. Please consider consumer harm reduction and personal freedom before supporting this bill.”

Share this everywhere. The hearing is May 20.

I received the samples from taking their survey. For me, personally, the best tasting was the green apple, and the rest were okay. The sour watermelon didn't really do much for me as far as effects, but the higher mg tabs were good. I only buy dolla tabs, though, so I wouldn't purchase them.

Just so you know, I'm not that smart...anymore. I often feel quite stupid, and hate asking questions that may have obvious answers.

My question is, why would a tablet burn my tongue? I have two tabs from two different vendors that always seem to burn when they're down to almost being dissolved, under my tongue. They both are beneficial as far as pain relief, but I hate that they burn so badly. Has anyone experienced this and why is it so?

NJ people and anyone who cares...e-mail all legislators from the Budget & Appropriations Committee to oppose S301. This is the committee for the next hearing that is not yet scheduled, but I do know that the earliest would be May 21st because now until May 20th are Budget Hearings only.

Sponsor of Bill: Shirley K Turner (NJ Senate District 15)

senturner@njleg.org

Senate Budget and Appropriations:

Carmen Amato (NJ Senate District 09)

senamato@njleg.org

Renee Burgess (NJ Senate District 28)

senburgess@njleg.org

John Burzichelli (NJ Senate District 3)

senburzichelli@njleg.org

Nilsa Cruz-Perez (NJ Senate District 5)

sencruzperez@njleg.org

Patrick Diegnan (NJ Senate District 18)

sendiegnan@njleg.org

Linda Greenstein - Vice Chair(NJ Senate District 14)

sengreenstein@njleg.org

Gordon Johnson (NJ Senate District 37)

senjohnson@njleg.org

Declan O'Scanlon (NJ Senate District 13)

senoscanlon@njleg.org

Teresa Ruiz (NJ Senate District 29)

senruiz@njleg.org

Paul Sarlo - Chair (NJ Senate District 36)

sensarlo@njleg.org

Douglas Steinhardt (NJ Senate District 23)

sensteinhardt@njleg.org

Mike Testa (NJ Senate District 1)

sentesta@njleg.org

Andrew Zwicker (NJ Senate District 16)

senzwicker@njleg.org

Budget & Appropriations:

https://www.billtrack50.com/committee/474

This is the official page for NJ Legislature

https://www.njleg.state.nj.us/committees/senate-committees

If you go to the menu, select Bills, Bill Subscription: you can subscribe to track bills and be notified by e-mail

The site also has the NJ Legislative Calendar where you can track to see when the hearing may be scheduled. It only has the schedule up until May 20th at this time. (Go to menu- Publications-Legislative Calendar-PDF)

E-mail Template:

I respectfully urge you to oppose S301 which would classify 7-hydroxymitragynine (7OH) products as a Schedule I substance.

"Your personal story"

I ask that you carefully consider the science. 7OH is not only naturally associated with kratom products—it is also formed in the body after consumption. Scheduling it could therefore have broader implications for kratom access as a whole, beyond what may be intended.

Policies should be grounded in science, evidence, and consumer safety—not confusion or overly broad classification. Many responsible consumers rely on 7OH as part of their daily lives, and sweeping restrictions could have serious unintended consequences. Individuals who depend on it for health or harm reduction may suffer greatly. Removing access risks pushing people toward unsafe alternatives, including illicit substances, or leaving them unable to function in daily life.

Rather than prohibition, I strongly encourage you to consider responsible regulation and consumer protections. A balanced regulatory framework could include:

• Limiting sales to adults age 21 and older

• Requiring third-party laboratory testing for purity and potency

• Mandating clear labeling of ingredients and alkaloid content

• Setting contaminant limits for heavy metals, microbes, and adulterants

• Implementing manufacturing and quality-control standards

• Restricting marketing that targets minors

These measures would directly address safety concerns while preserving access for responsible adults.

The science surrounding kratom and its alkaloids (7OH) is still evolving, and I respectfully ask that policy decisions reflect a careful, evidence-based approach. For many of us, this is not about recreation—it is about maintaining the ability to function and live a stable life.

Thank you for your time and consideration.